🔥 15 cardiology trials from ESC 2026 worth knowing

🔥🔥🔥 Practice-changing

• ACACIA-HCM — Aficamten improves symptoms + exercise capacity in non-obstructive HCM
• TRIC-I-HF — TTVR ↓ death/HF hospitalization in severe TR
• STAREE — Atorvastatin ↓ major CV events in adults ≥70 without prior CVD
• SINGLE-AF — Apixaban in intermediate-risk AF: potential guideline changer
• AIR-STEMI — Physiology-guided complete PCI improves outcomes vs angiographic guidance

🔥🔥 Major signals

• CARDIO-TTRansform — Eplontersen fails to reduce CV death/recurrent CV events in ATTR-CM
• SHASTA-3/4 — Plozasiran ↓ TG ~80% + ↓ pancreatitis
• PVI-SHAM-AF — PVI ↓ AF recurrence, but no QoL advantage over sham
• PRAGUE-26 — Catheter-directed therapy improves early outcomes in intermediate-high-risk PE
• POPular ACE TAVI — Routine protamine after TAVI appears beneficial

🔥 Important negatives / safety

• LIBREXIA ACS — Milvexian neutral after ACS
• AMUNDSEN — Early PCSK9 inhibition ↓ LDL, but no early clinical outcome benefit
• ENRICH-AF — Edoxaban after ICH ↑ bleeding risk
• DISCO — Immediate cath provides no benefit after OHCA without STEMI
• NOTION-4 — Routine post-TAVI DOAC strategy looks harmful

ESC 2026 takeaway:
Big wins in HCM and tricuspid intervention, important AF and lipid questions answered, and several negative trials that may be just as practice-relevant.

#ESC2026 #Cardiology #MedVitaHash #CardioVitaHash